United Therapeutics CORP Form 4 insider transactions

United Therapeutics Director Ray Kurzweil reported the vesting of restricted stock units and the acquisition of new equity awards.

United Therapeutics Director Richard Giltner reported the vesting of 1,190 restricted stock units and the award of 1,310 new restricted stock units.

United Therapeutics Director Louis W. Sullivan increased his beneficial ownership through RSU vesting and new equity awards, signaling continued alignment with shareholder interests.

United Therapeutics Corp director Raymond Dwek was granted 3,650 stock options as part of an annual non-employee director award, exercisable from July 9, 2026.

United Therapeutics Director Christopher Causey reported the vesting of restricted stock units and the grant of new stock options.

United Therapeutics Corporation Director Jan Malcolm reported the vesting of restricted stock units and the grant of new equity awards, including stock options and additional restricted stock units.

Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corporation, exercised stock options and subsequently sold an equivalent number of shares as part of a pre-arranged trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp., executed a planned exercise of stock options and subsequent sale of common shares on July 10, 2025, as disclosed in a recent SEC Form 4 filing.

Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp, completed a pre-arranged exercise of stock options and subsequent sale of common stock totaling 11,000 shares on June 26, 2025.

Nilda Mesa, a Director at United Therapeutics Corp (UTHR), reported the sale of 645 shares of common stock for approximately $289.99 per share under a Rule 10b5-1 plan.

A director at United Therapeutics Corp. exercised stock options and subsequently sold a portion of the acquired shares in a cashless transaction.

Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp., exercised stock options and sold the resulting shares totaling 11,000 under a pre-arranged 10b5-1 plan.

United Therapeutics Corporation's CFO and Treasurer, James Edgemond, exercised stock options and sold 12,000 shares of common stock on June 9, 2025, as part of a pre-arranged 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), exercised stock options and subsequently sold common stock shares on June 2, 2025, as part of a pre-arranged 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp., exercised stock options and simultaneously sold 11,000 shares of common stock for approximately $3.47 million under a pre-arranged 10b5-1 plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares on May 15, 2025, according to a pre-arranged 10b5-1 plan.

Director Tommy G. Thompson exercised stock options and sold shares of United Therapeutics Corp on May 9, 2025.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on May 1, 2025, under a pre-arranged 10b5-1 trading plan.

Raymond Dwek, a director at United Therapeutics, exercised stock options and sold the resulting shares according to a pre-arranged 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on April 17, 2025, according to a pre-arranged 10b5-1 trading plan.

Director Raymond Dwek exercised stock options and sold shares of United Therapeutics Corp on April 14, 2025, according to a Form 4 filing.

Director Raymond Dwek exercised stock options and sold the resulting shares of United Therapeutics Corp (UTHR) on April 7, 2025, under a pre-arranged 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on April 3, 2025, according to a Form 4 filing with the SEC.

Director Tommy G. Thompson exercised stock options and sold shares of United Therapeutics Corp on March 24, 2025.

Director Christopher Patusky exercised stock options and sold shares of United Therapeutics Corp (UTHR) on March 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, reports a transfer of shares between family trusts in a recent SEC filing.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, executed share tracking awards and disposed of common stock under a pre-arranged 10b5-1 plan.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on March 3, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Director Ray Kurzweil exercised stock options and sold shares of United Therapeutics Corp on February 28, 2025.